Superworth

CytomX Therapeutics profit margin CTMX

Gross, operating and net profit as a share of revenue over the last twelve months, from 2017.

Net margin, 12 months
n/m
not a meaningful number
Peer median
11.6%

CytomX Therapeutics' net margin works out at −435% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025−22.8%−29.4%
FY202423.1%18.1%
FY2023−0.6%−6.4%
FY2022n/an/a
FY2021n/an/a
FY2020−94.7%n/a
FY2019n/an/a
FY2018n/an/a
FY2017−60.2%−64.6%
FY2016n/an/a
FY2015n/an/a
FY2014n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY25−22.8%−45.9 pts−29.4%
Q3 FY2524.7%+13.7 pts20.5%
Q2 FY2534.0%+24.7 pts30.6%
Q1 FY2528.2%+14.3 pts24.4%
Q4 FY2423.1%+23.6 pts18.1%
Q3 FY2410.9%+21.7 pts5.3%
Q2 FY249.3%+62.4 pts4.8%
Q1 FY2413.9%n/a9.1%
Q4 FY23−0.6%n/a−6.4%
Q3 FY23−10.7%n/a−16.2%

Against its peers

Companies in Drug Manufacturers - General nearest CytomX Therapeutics' size, closest first, today.

CompanyProfit margin
CTMXCytomX Therapeuticsn/m
ARVNArvinas2.9%
PBYIPuma Biotechnology11.6%
IRWDIronwood Pharmaceuticals33.4%
ZVRAZevra Therapeutics42.8%
CRMDCorMedix40.5%
COLLCollegium Pharmaceutical5.9%
ABUSArbutus Biopharma84.2%
AMPHAmphastar Pharmaceuticals10.8%
NATRNatures Sunshine Products3.7%
OMEROmerosn/m
Peer median11.6%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on CytomX Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.